Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Weiß, J.; Csőszi, Tibor; Maglakelidze, Marina; J. Hoyer, Robert; Beck, J.T.; Dómine Gómez, M.; Łowczak, Anna; Aljumaily, Raid; M. Rocha Lima, Caio; V. Boccia, Ralph; T. Hanna, Wahid; Nikolinakos, Petros; Chiu, V.K.; K. Owonikoko, Taofeek; R. Schuster, Steven; Hussein, Maen; Richards, Donald; Sawrycki, Piotr; Bulat, Iurie; Hamm, John; L. Hart, Lowell; Adler, S.; Antal, Joyce; Y. Lai, Anne; A. Sorrentino, Jessica; Yang, Z.; Malik, Rajesh; R. Morris, Shannon; J. Roberts, Patrick; Dragnev, K.

doi:10.1093/annonc/mdz278

Public

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Published in Annals of Oncology • Aug 22, 2019

Authors:

J. Weiß

Tibor Csőszi

Marina Maglakelidze

Abstract

BACKGROUND: Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function during chemotherapy (myelopreservation). Preclinicall...

Subject

Medicine

Chemotherapy

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!